Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Trial Profile

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs PB 1046 (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors PhaseBio Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 04 Feb 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 16 Jan 2014 Planned End Date changed from 1 Sep 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top